Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08049820 DDI Study with Oral Contraceptives, Midazolam, and Dabigatran in Healthy Females
NCT07190430Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-08049820 in atopic dermatitis (AD) (6 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve of Midazolam at 24 hours, Maximum Plasma Concentration of Midazolam at 24 hours and 4 more. Started Oct 2025; status: completed.
02
Drugs
PF-08049820
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07190430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07190430.